OctaAlpha1 / Octapharma  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
OctaAlpha1 / Octapharma
NCT03385395: Study Comparing Weekly Intravenous Administration of OctaAlpha1 With a Marketed Preparation Glassia® in Subjects With Alpha-1-antitrypsin Deficiency

Withdrawn
2
0
NA
OctaAlpha1, Glassia
Octapharma
Alpha 1-Antitrypsin Deficiency
12/19
12/19

Download Options